Albert Bourla | |
---|---|
Άλμπερτ Μπουρλά | |
Born | Άλμπερτ Μπουρλά[1] October 21, 1961 Thessaloniki, Greece |
Education | Aristotle University of Thessaloniki (PhD, DVM) |
Employer | Pfizer |
Title | Chairman and CEO of Pfizer |
Board member of | |
Spouse | Myriam Alchanati |
Children | 2 |
Honours | Golden Cross of the Order of the Redeemer[2] |
Albert Bourla (Greek: Άλμπερτ Μπουρλά; born October 21, 1961) is a Greek-American veterinarian and businessman known for serving as the chairman and chief executive officer of the pharmaceutical company Pfizer. He joined the company in 1993 and has held several executive roles across Pfizer's divisions. Prior to becoming chief executive officer, Bourla was chief operating officer.
In addition to the boards of Pfizer and the Pfizer Foundation, Bourla is or has been on the boards of the Biotechnology Innovation Organization, Catalyst, the Partnership for New York City, and the Pharmaceutical Research and Manufacturers of America. he is also a member of The Business Council and the Business Roundtable.
Bourla reshaped Pfizer to focus on research and development. He is also credited with helping the development of Improvac, which eradicates boar taint, and for refocusing Pfizer's vaccine division to focus on Staphylococcus, Clostridioides difficile infection, infant diseases, and the Pfizer–BioNTech COVID-19 vaccine. Bourla opposes government interference in pharmaceutical pricing, which he argues would hamper spending on development of new drugs.[3]
Bourla was awarded the 2022 Genesis Prize for his leadership in the development of the Pfizer–BioNTech COVID-19 vaccine.[4]
nationaljournal
was invoked but never defined (see the help page).